Henrietta Lacks, HeLa Cells, and Cell Culture Contamination

Vaccine Development, Vaccine Snafus

Henrietta Lacks, HeLa Cells, and Cell Culture Contamination

No Comments 10 March 2010

.
.
.
.
.

Brendan P. Lucey, MD, Walter A. Nelson-Rees, PhD, and Grover M. Hutchins, MDFrom the Department of Neurology, Michael O’Callaghan Federal Hospital, Nellis Air Force Base, Nevada (Dr Lucey); and the Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland (Dr Hutchins).

Abstract

Henrietta Lacks died in 1951 of an aggressive adenocarcinoma of the cervix. A tissue biopsy obtained for diagnostic evaluation yielded additional tissue for Dr George O. Gey’s tissue culture laboratory at Johns Hopkins (Baltimore, Maryland). The cancer cells, now called HeLa cells, grew rapidly in cell culture and became the first human cell line. HeLa cells were used by researchers around the world. However, 20 years after Henrietta Lacks’ death, mounting evidence suggested that HeLa cells contaminated and overgrew other cell lines. Cultures, supposedly of tissues such as breast cancer or mouse, proved to be HeLa cells. We describe the history behind the development of HeLa cells, including the first published description of Ms Lacks’ autopsy, and the cell culture contamination that resulted. The debate over cell culture contamination began in the 1970s and was not harmonious. Ultimately, the problem was not resolved and it continues today. Finally, we discuss the philosophical implications of the immortal HeLa cell line.

Accepted: March 6, 2009

Deceased. Dr Nelson-Rees, retired, contributed significantly to the manuscript before his death.

Reprints: Brendan P. Lucey, MD, Department of Neurology, Michael O’Callaghan Federal Hospital, Nellis Air Force Base, 1400 N Las Vegas Blvd, Nevada 89191 (brendanlucey@hotmail.com).

HENRIETTA LACKS

On February 1, 1951, a 30-year-old woman named Henrietta Lacks presented to the Johns Hopkins Gynecology Clinic in Baltimore, Maryland, for symptoms of spotting between her menstrual periods. Her last menstrual period had been on January 4, 1951.1 Although the results of her general examination were unremarkable, examination of the cervix revealed a raised, smooth, glistening, and purple lesion less than 2.54 cm (1 inch) in size.2 The lesion was confined to the cervix and appeared different from other carcinomas of the cervix seen by the treating physician. It was later noted in the autopsy report3 by Ella Oppenheimer, MD, that “1 year before death the patient delivered a normal infant and 6 weeks later her cervix was said to be normal. Three months later she presented herself to the clinic with a 2–3 cm cervical tumor.” Results of tests for sexually transmitted diseases were negative and a biopsy of the cervix was performed. Four pieces of tissue from the biopsy were sent to the pathology department and “epidermoid carcinoma, cervix uteri, spinal cell type” was diagnosed with definite invasion of the stroma (Figure 1).1

During the next several months, the patient received 4800 mg-h of radium and 11500 R (roentgen) of deep x-ray.3 Treatment failed to prevent spread of the cancer, however, and it extended relatively rapidly to both parametria. On August 8, 1951, she developed severe abdominal pain and was admitted to The Johns Hopkins Hospital (Baltimore, Maryland). Her pain became progressively more severe and intractable. Because of failure to void urine, ureteral catheterization was unsuccessfully attempted several times and the serum level of nonprotein nitrogen rose to from 120 to 150 mg/dL (reference range, 25-50 mg/dL). Diathermy therapy was tried without positive effect. Henrietta Lacks died at 12:15 am on October 4, 1951.3

THE AUTOPSY

Ms Lacks’ autopsy was performed at 10:30 am on the same day as her death. Examination of the body revealed a “well-developed, thin, colored female [with] deeply pigmented skin over the lower abdomen such as seen after x-ray treatment.”3 The peritoneal cavity contained a small amount of yellowish fluid and approximately 1 L of fluid was found in the pleural cavity, but the pericardium was devoid of fluid. The lungs were noted to have bibasilar lobar pneumonia with cheesy material in the bronchi. The mucosa of the bronchi was blood stained. The cranial cavity and neck organs were not examined because permission was not granted.

Small, white, and firm nodules were observed throughout both the thoracic and abdominal cavities, including the surfaces of the peritoneum, the entire length of the intestines, and the surface of the liver. Furthermore, both the pleural surface and the superior surface of the diaphragm (right side more than the left side) were covered with nodules, as were the lung, liver parenchyma, and the pericardium. The nodules varied slightly in size, measuring from 8 mm in diameter on the peritoneal surface to 1 cm in the lung parenchyma. However, the largest mesenteric lymph node infiltrated with tumor was 6 cm in length. Small tumor nodules, 3 mm in diameter, were seen in each adrenal gland. At the apex of the right ventricle, a tumor nodule approximately 1 cm in diameter protruded into the lumen. Relatively little necrosis was seen in any of the nodules.

A large subcapsular hematoma was present at the superior pole of the right kidney and a tumor nodule had grown into the capsule. Bilaterally, the ureters, calyces, and pelves were markedly dilated, consistent with severe hydronephrosis. The left ureter was involved in a mass of tumor just inside the brim of the pelvis, while a tumor mass near the posterior wall of the bladder entangled the right ureter. The bladder itself was adherent to the anterior abdominal wall. Many small nodules were seen on the bladder mucosa, and the external surface was nearly a solid mass of tumor.

The right ureter was dilated within 4 cm of the bladder, where the dilatation ceased abruptly. At this level, the circumference of the ureter was 14 mm; distally, the right ureter had been left intact and a probe passed with some difficulty down to the bladder. The probe could not be passed through the left ureter to the bladder, although both ureteral openings appeared patent from within the bladder. Closer examination revealed that the left ureter was dilated to the bladder wall, at which point a mass of tumor on the external surface caused the obstruction. The bladder was partially surrounded by nodular masses of tumor that penetrated the bladder wall, particularly in the trigone area. The bladder was not especially dilated. Tumor was seen infiltrating the wall of the vagina and friable masses of tumor replaced the cervix. The uterus was approximately normal in size and covered with tumor nodules, while the fallopian tubes and ovaries were obliterated by clusters of tumor nodules. A mass of tumor surrounded the iliac veins, and the area of the right iliac vein appeared to have tumor entering its lumen. Focal uremic diphtheritic colitis was also noted.

HeLa CELLS

Henrietta Lacks’ cervical biopsy supplied tissue to the pathology department for clinical evaluation and to the Tissue Culture Laboratory in the Department of Surgery at The Johns Hopkins Hospital for research purposes. In 1951, George Gey, MD, was director of the laboratory and had already spent many years at Johns Hopkins as a student and faculty member. Prominent scientists at Johns Hopkins, such as Ross Harrison, MD, PhD, and Warren Lewis, MD, made important contributions to the history of tissue culture.4,5 Dr Gey and his wife and chief collaborator, Margaret Gey, RN, continued in this tradition and began working on tissue culture in association with Dr Lewis in 1922. Dr Gey’s work grew to encompass in vitro investigations related to endocrinology, cancer, and virology in addition to intracellular and membrane cytology.4 However, his greatest scientific contribution was due to Henrietta Lacks.

While Henrietta Lacks was treated at Johns Hopkins, Dr Gey was attempting to fulfill ambitious goals for the Tissue Culture Laboratory, that is, “the isolation and maintenance of normal and malignant or otherwise diseased tissues as temporary or stable organoids or as derived cell strains.”6 Toward this purpose, Dr Gey and his colleagues collected tissue from surgical procedures throughout the hospital.7 Approximately 30 specimens of cervical cancer had been sent to the laboratory of Dr Gey by the time Ms Lacks presented to the gynecology clinic.2 An investigator in the laboratory, Mary Kubicek (Figure 2), placed cells obtained from the biopsy specimen of Henrietta Lacks into culture by using the roller-tube technique; the cells grew robustly, contrary to the results with previous specimens, becoming the first human cancer cell line immortalized in tissue culture. The cells were named “HeLa” after the initial 2 letters of Henrietta Lacks’ first and last names. She would not be credited as the originator of the cell line for many years, and HeLa cells were misinterpreted as originating with “Harriet Lane” or “Helen Lane” for years.7,8

Previous efforts to grow either normal cervical epithelium or cervical carcinoma in culture proved elusive9; however, efforts to grow cells from the aggressive adenocarcinoma of the cervix that had affected Henrietta Lacks were successful. Twenty years later, reexamination of the histopathology slides from Ms Lacks’ surgical biopsy and autopsy led to a revision of the initial diagnosis, with the finding that the patient had a very aggressive adenocarcinoma of the cervix.9 The cervical carcinoma was clearly very malignant and the patient had a rapid clinical deterioration. Although the concept of rapidly progressive cervical carcinoma has been questioned,10 this case history would suggest otherwise. Recently, HeLa cells have been shown to contain human papillomavirus (HPV) 18 DNA11 and HPV18-positive HeLa cells have been linked to changes in microRNA expression.12 Since HPV18 has been associated with very aggressive adenocarcinomas, this finding may explain why Dr Gey was surprised by the prolific growth of HeLa cells in culture. Routine Papanicolaou smear screening may not detect rapidly progressive cervical carcinomas; the new HPV vaccine holds the promise of preventing these tumors.

Gey and colleagues13 published data with HeLa cells in 1952, reporting the “evaluation in vitro of the growth potential of normal, early intra-epithelial, and invasive carcinoma from a series of cases of cervical carcinoma.” Only 1 strain of cervical carcinoma cells was established in “continuous roller-tube cultures for almost a year,” which grew in a medium of chicken plasma, bovine embryo extract, and human placental cord serum: HeLa.13 Dr Gey’s roller-tube technique for tissue culture was another significant scientific contribution and was used by John Enders, PhD, and colleagues in their work cultivating poliomyelitis virus in nonnervous system tissue.4 Perhaps less well known in the history of poliomyelitis research is that Dr Gey successfully propagated poliomyelitis viruses in HeLa cell culture.14

TISSUE CULTURE CONTAMINATION

George Gey was generous with requests for HeLa cells. Since HeLa cells were a robust, immortal cell line, easily propagated over generations in culture, Dr Gey supplied samples to scientists in the United States and internationally who were interested in studying the first established human cancer cell line. HeLa cells proliferated in cultures around the world and, as the years passed, evidence accumulated that HeLa cells had contaminated other cell lines. Interspecies cross-contamination with HeLa, easier to detect than intraspecies contamination, was described in the early 1960s.15,16

Several years later, in 1967, intraspecies contamination of cell lines became more readily detectable through the work of Stanley Gartler, PhD.17 He described apparent HeLa cell contamination of 19 other human cell lines by using a technique of isoenzyme analysis of glucose-6-phosphate dehydrogenase (G6PD) and phosphoglucomutase (PGM) electrophoretic polymorphisms; all cell lines had the same G6PD type A and PGM type 1 phenotypes.18 The G6PD type A variant is sex-linked and found at an increased frequency in the African American population. The phosphoglucomutase gene is autosomal and has 3 common variants. The likelihood of all cell lines having these 2 isoenzyme variants was low, and several of the tested cell lines were known to be from whites. Gartler18 noted that “with the continued expansion of cell culture technology, it is almost certain that both interspecific and intraspecific contamination will occur.” He hypothesized that the G6PD subtype could have changed because of multiple divisions in culture, but he later demonstrated the stability of isoenzymes in cell culture lines over time.19

Methods for identifying cell lines were not limited to isoenzyme phenotypes. Karyotyping and chromosome band analysis were added to the arsenal of techniques available. Chromosome band analysis involved limited trypsin digestion of histone proteins followed by Giemsa staining20; controlled exposure of nucleoproteins to trypsin resulted in their partial removal and revealed Giemsa-stained bands. The technique was time-consuming but reliable in experienced hands. Thus, in the early 1970s, the state of the art for HeLa cell identification included presence of G6PD type A, lack of a Y chromosome, and identification of a specific pattern of banded-marker chromosomes21; these 3 three findings were thought sufficient to define a cell line as HeLa.

In 1974, 5 cell lines—reportedly of human lineage and infected with animal viruses—were sent to the United States from the Soviet Union. All of the cell lines were revealed to be HeLa in origin.22 In a story previously detailed,7 the realization that HeLa cells had contaminated cultures so far afield led to a reappraisal of tissue culture stocks by the American Type Culture Collection (ATCC; Manassas, Virginia) and the Cell Culture Laboratory at the Naval Biosciences Laboratory (Oakland, California).21–27 For instance, a follow-up study to the proper identification of the Soviet Union cell lines implicated HeLa cells as contaminants of several other cell lines.23 The ATCC found that 27 of 56 cell lines had G6PD type A variant.24 Further analysis revealed that several of these cell lines possessed some, but not all, HeLa markers. It was hypothesized that these variations could represent somatic cell hybridization between the original cell line and the contaminating HeLa cells.

During the previous quarter century, Dr Gey’s samples of HeLa cells had multiplied in laboratories throughout the world, as they were transferred from researcher to researcher and across international borders. Several hypotheses were offered for HeLa cells’ remarkable growth beyond what might be expected of a very aggressive cervical adenocarcinoma. As the first human cancer cell line, and a potent cell at baseline, it had been selected to survive in culture after countless passages, cell divisions, and viral infections. In the battle for reproduction, HeLa was best selected to outcompete other cell lines and eventually overgrew other cultures it invaded. Another possible explanation was that cell lines often came from outside laboratories. Prior to their deposition in tissue culture collection banks, the cell lines had been subjected to variable laboratory techniques. Furthermore, these laboratories undoubtedly possessed other cell lines such as the ubiquitous HeLa. Since HeLa cell contamination has been reported from air droplets,28 poor laboratory technique would suffice to rapidly contaminate other cell lines, which would then be passed on to subsequent laboratories.24,29

CELL CULTURE CONTROVERSY

The debate over cell culture contamination was not always harmonious.7,30 Contaminated cell lines went far beyond HeLa cells. In one study, human breast cancer cell lines were found to have both intraspecies and interspecies contamination. Other cell lines reported to be human cells were actually derived from hamster, rat, mouse, mongoose, or mink; gibbon cells were actually human cells; horse cells were dog cells.25 In total, 41 of 253 cell lines (16%) were not what they had been purported to be. Years of research and numerous academic careers were built on the presumed identity of various cell lines, and clarifying incorrect data required repudiating previously reported results.31 Alternative explanations for HeLa cell contamination were offered in some instances.32

Unfortunately, the impact of cell culture contamination extended far beyond the relatively narrow field of cytobiology and the researchers studying cell lines. For example, radiobiologists investigating the relation of radiation doses to cell death in human kidney cells were surprised to discover that the cells they thought were derived from human kidney were actually HeLa.26 Controversy erupted regarding the interpretation of their results: how did irradiating malignant cells translate to normal cells when evaluating cell death?33 The debate even ensnared Jonas Salk, MD, who stated at a conference in October 1978 that he had injected study subjects, enrolled in a vaccine trial, with HeLa cells that had contaminated his cultures7; however, any mention of HeLa failed to find its way into his published remarks regarding the “‘theoretical’ possibility of transmitting a neoplasia-inducing factor.”34

HeLa CELLS AND CELL CULTURE CONTAMINATION TODAY

Despite the passing of nearly 50 years since the problem first surfaced of HeLa cell contamination of tissue cultures and despite the explosive advances in molecular biology, cell culture contamination remains an important issue for the scientific community.35–38 The problem extends far beyond HeLa cells, although they remain a culprit.38 In one study, 45 of 252 human cell lines (18%) supplied by 27 of 93 originators (29%) were contaminated.39 Most of the contaminants were intraspecies cells, suggesting improved detection of interspecies contamination, but still concerning. New techniques, such as amplification of minisatellite-region DNA40 and short tandem repeat profiling,41 which are faster and more precise than older techniques such as chromosome banding, have not been widely adopted in a standardized, universal fashion. Fortunately, there was recently a call to action on preventing contaminated cell lines.42

CONCLUSION

Philosophically, we wonder if Henrietta Lacks has achieved a kind of corporeal immortality through her eponymous cell line. Sir William Osler, MD, delivering the Ingersoll Lectureship titled “Science and Immortality” at Harvard University, Boston, Massachusetts, in 1904 pondered new lessons from modern embryology and how they may impact the meaning of death. Although he obviously knew nothing of cell lines or DNA, he could marvel that “the individual is nothing more than the transient off-shoot of a germ plasm, which has an unbroken continuity from generation to generation, from age to age … ‘the individual organism is transient, but its embryonic substance, which produces the mortal tissues, preserves itself imperishable, everlasting, and constant.’43

It is impossible to know what Dr Osler would have thought about immortal HeLa cells. Has Henrietta Lacks’ “germ plasm” or “embryonic substance” (her DNA) provided her with an unbroken, unaltered chain to the present day so that we can claim that HeLa cells are Henrietta Lacks? Or, has her DNA evolved into a new entity—Helacyton gartleri has been suggested44—after countless cell culture passages, viral infections, and other cell line contaminants? Although the question of whether or not such a new species has evolved in the cell cultures of laboratories around the world is difficult to answer, as molecular biology continues to expand the frontiers of our knowledge at breathtaking speed, this question may need to be answered to fully comprehend both the findings of experiments performed on HeLa cells and the ethical implications of creating what may be regarded as a new organism.

References
1. Surgical Biopsy Number 92498. Baltimore, MD: Department of Pathology, The Johns Hopkins Hospital; 1951.
2. Jones, H. W. Record of the first physician to see Henrietta Lacks at the Johns Hopkins Hospital: history of the beginning of the HeLa cell line. Am J Obstet Gynecol 1997. 176:227S–228S.
3. Autopsy Protocol 23260. Baltimore, MD: Autopsy Records of The Johns Hopkins Hospital; 1951.
4. Harvey, A. M. Johns Hopkins—the birthplace of tissue culture: the story of Ross G. Harrison, Warren H. Lewis, and George O. Gey. Johns Hopkins Med J Suppl. 1976:114–123.
5. Bang, F. B. History of tissue culture at Johns Hopkins. Bull Hist Med 1977. 51:516–537.
6. Gey, G. O. Some Aspects of the Constitution and Behavior of Normal and Malignant Cells in Continuous Culture. New York, NY: Academic Press; 1955. The Harvey Lectures, Series L, 1954–1955..
7. Gold, M. A Conspiracy of Cells: One Woman’s Immortal Legacy and the Medical Scandal It Caused. Albany, NY: State University of New York Press; 1986.
8. Culliton, B. J. HeLa cells: contaminating cultures around the world. Science 1974. 184:1058–1059.
9. Jones, H. W. , V. A. McKusick , P. S. Harper , and K. D. Wuu . George Otto Gey: the HeLa cell and a reappraisal of its origin. Obstet Gynecol 1971. 38 (6):945–949.
10. Schwartz, P. E. , O. Hadjimichael , D. M. Lowell , M. J. Merino , and D. Janerich . Rapidly progressive cervical cancer: the Connecticut experience. Am J Obstet Gynecol 1996. 175:1105–1109.
11. Meissner, J. D. Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSki, SiHa, and HeLa cervical carcinoma cell lines. J Gen Virol 1999. 80:1725–1733.
12. Martinez, I. , A. S. Gardiner , K. F. Board , F. A. Monzon , R. P. Edwards , and S. A. Khan . Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 2008. 27:2575–2582.
13. Gey, G. O. , W. D. Coffman , and M. T. Kubicek . Tissue culture studies of the proliferative capacity of cervical carcinoma and normal epithelium. Cancer Res 1952. 12:264–265.
14. Scherer, W. F. , J. T. Syverton , and G. O. Gey . Studies on the propagation in vitro of poliomyelitis viruses. J Exp Med 1953. 97:695–710.
15. Defendi, V. , R. E. Billingham , W. K. Silvers , and P. Moorhead . Immunological and karyological criteria for identification of cell lines. J Natl Cancer Inst 1960. 25:359–385.
16. Brand, K. G. and J. T. Syverton . Results of species-specific hemagglutination tests on “transformed,” nontransformed, and primary cell cultures. J Natl Cancer Inst 1962. 28:147–157.
17. Gartler, S. M. Genetic markers as tracers in cell culture. In: Westfall BB, ed. Second Decennial Review Conference on Cell Tissue and Organ Culture. Washington, DC: US Government Printing Office; 1967:167–195. National Cancer Institute Monograph No. 26..
18. Gartler, S. M. Apparent HeLa cell contamination of human heteroploid cell lines. Nature 1968. 217:750–751.
19. Auersperg, N. and S. M. Gartler . Isoenzyme stability in human heteroploid cell lines. Exp Cell Res 1970. 61:465–467.
20. Wang, H. C. and S. Fedoroff . Karyology of cells in culture: trypsin technique to reveal G-bands. In: Kruse PF Jr, Patterson MK Jr, eds. Tissue Culture Methods and Applications. New York, NY: Academic Press; 1973:782–787.
21. Nelson-Rees, W. A. and R. R. Flandermeyer . HeLa cultures defined. Science 1976. 191:96–98.
22. Nelson-Rees, W. A. , V. M. Zhdanov , P. K. Hawthorne , and R. R. Flandermeyer . HeLa-like marker chromosomes and type-A variant glucose-6-phosphate dehydrogenase isoenzyme in human cell cultures producing Mason-Pfizer monkey virus-like particles. J Natl Cancer Inst 1974. 53:751–757.
23. Nelson-Rees, W. A. , R. R. Flandermeyer , and P. K. Hawthorne . Banded marker chromosomes as indicators of intraspecies cellular contamination. Science 1974. 184:1093–1096.
24. Lavappa, K. S. , M. L. Macy , and J. E. Shannon . Examination of ATCC stocks for HeLa marker chromosomes in human cell lines. Nature 1976. 259:211–213.
25. Nelson-Rees, W. A. and R. R. Flandermeyer . Inter- and intraspecies contamination of human breast tumor cell lines HBC and BrCa5 and other cell cultures. Science 1977. 195:1343–1344.
26. Nelson-Rees, W. A. , R. R. Flandermeyer , and D. W. Daniels . T-1 cells are HeLa and not of normal human kidney origin. Science 1980. 209:719–720.
27. Nelson-Rees, W. A. , D. W. Daniels , and R. R. Flandermeyer . Cross-contamination of cells in culture. Science 1981. 212:446–452.
28. Coriell, L. Detection and Elimination of Contaminating Organisms. Bethesda, MD: US Department of Health, Education and Welfare; 1962. National Cancer Institute Monograph No. 7..
29. Grimwade, S. HeLa takes over. Nature 1976. 259:172.
30. Chatterjee, R. Cases of mistaken identity. Science 2007. 315:928–931.
31. Nelson-Rees, W. A. , R. A. Akeson , and R. Cailleau . Lung organ-specific antigens on cells with HeLa marker chromosomes. J Natl Cancer Inst 1978. 60 (6):1205–1207.
32. Pathak, S. , M. J. Siciliano , R. Cailleau , C. L. Wiseman , and T. C. Hsu . A human breast adenocarcinoma with chromosome and isoenzyme markers similar to those of the HeLa line. J Natl Cancer Inst 1979. 62 (2):263–271.
33. Broad, W. J. The case of the unmentioned malignancy. Science 1980. 210:1229–1230.
34. Salk, J. The spector of malignancy and criteria for cell lines as substrates for vaccines. In: Petricciani JC, Hopps HE, Chapple P, eds. Cell Substrates and Their Use in the Production of Vaccines and Other Biologicals. New York, NY: Plenum Press; 1979:107–113.
35. Stacey, G. N. , J. R. W. Masters , R. J. Hay , H. G. Drexler , R. A. F. MacLeod , and R. I. Freshney . Cell contamination leads to inaccurate data: we must take action now. Nature 2000. 403:356.
36. Masters, J. R. HeLa cells 50 years on: the good, the bad and the ugly. Nat Rev Cancer 2002. 2:315–319.
37. Nardone, R. M. Eradication of cross-contaminated cell lines: a call for action. Cell Biol Toxicol 2007. 23 (6):367–372.
38. Lucey, D. J. , M. A. Walsh , and R. Costello . Imposter cell lines. Laryngoscope 2006. 116:161–162.
39. MacLeod, R. A. F. , W. G. Dirks , Y. Matsuo , M. Kaufmann , H. Milch , and H. G. Drexler . Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int J Cancer 1999. 83:555–563.
40. Silva, L. M. , H. Montes de Oca , C. R. Diniz , and C. L. Fortes-Dias . Fingerprinting of cell lines by directed amplication of minisatellite-region DNA (DAMD). Braz J Med Biol Res 2001. 34:1405–1410.
41. Masters, J. R. , J. A. Thomson , and B. Daly-Burns . et al. Short tandem repeat profiling provides an international reference standard for human cell lines. PNAS 2001. 98 (14):8012–8017.
42. Lacroix, M. Persistent use of “false” cell lines. Int J Cancer 2008. 122:1–4.
43. Osler, W. Science and Immortality: The Ingersoll Lecture, 1904. New York, NY: Arno Press; 1977.
44. Van Valen, L. M. and V. C. Maiorana . HeLa, a new microbial species. Evol Theor Rev 1991. 10 (1):71–74.
Share and Enjoy:
  • Print
  • Digg
  • del.icio.us
  • Facebook
  • StumbleUpon
  • Twitter
  • Yahoo! Buzz
  • PDF
  • LinkedIn
  • Live
  • NewsVine
Gardasil Primer: Doctors & vaccine injured families speak out

Gardasil, HPV, Top Stories, Vaccine Snafus, Video

Gardasil Primer: Doctors & vaccine injured families speak out

No Comments 03 March 2010

Share and Enjoy:
  • Print
  • Digg
  • del.icio.us
  • Facebook
  • StumbleUpon
  • Twitter
  • Yahoo! Buzz
  • PDF
  • LinkedIn
  • Live
  • NewsVine
Activists: Uzbekistan orders forced sterilizations

Top Stories, Undue Influence, Vaccine Propaganda, Vaccine Snafus

Activists: Uzbekistan orders forced sterilizations

No Comments 02 March 2010

Yahoo News

MOSCOW – An independent think-tank and a rights group in Uzbekistan claim that authorities have instructed health workers to surgically sterilize women as part of a government campaign to reduce the birth rate in the authoritarian ex-Soviet nation.

The Expert Working Group claimed Tuesday that a Health Ministry decree has ordered doctors to conduct hysterectomies on tens of thousands of women in the Central Asian nation.

The Najot rights group reported “numerous” cases of forced sterilization in maternity hospitals where doctors allegedly sterilize women without their consent.

Uzbek health officials did not answer repeated phone calls seeking comment.

A human right activist who made similar allegations in 2005 was jailed for alleged anti-government actions.

Share and Enjoy:
  • Print
  • Digg
  • del.icio.us
  • Facebook
  • StumbleUpon
  • Twitter
  • Yahoo! Buzz
  • PDF
  • LinkedIn
  • Live
  • NewsVine
Kenya: Trial HIV Vaccine Leaves 46 Infected

AIDS, Infection, Top Stories, Vaccine Snafus

Kenya: Trial HIV Vaccine Leaves 46 Infected

No Comments 20 January 2010

.
.
.

Elias Mbao
AllAfrica.com
12 January 2010

Lusaka — A failed clinical trial HIV vaccine that left 46 Zambian women infected with the virus has sparked controversy.

The Microbicides Development Programme (MDP) 301 trial, which was testing if the gel PRO2000 would prevent HIV infection took place between September 2005 and 2009.

It was conducted at six research centres in South Africa, Tanzania, Uganda and Zambia and 9,385 participated.

From the Zambian site in Mazabuka district – about 160 kilometres South West of the capital Lusaka – 1, 332

HIV negative women were recruited but the results, which the Ministry of Health does not wish to comment on, revealed that between 46 and 50 of women that participated in the clinical trial contracted HIV despite using PRO2000 gel before sex.

“Some participants did become HIV positive because the study was conducted in the normal environment,” confirmed Dr Maureen Chisembele, principal investigator for Microbicides Development Programme Zambia – a subsidiary of the UK based research entity.

“Women who became infected during the study were given further counselling and referred to local health services for ART (antiretroviral therapy).”

The National Aids Council of Zambia (NAC), a government unit mandated to oversee HIV/Aids programme, confirmed that 50 out of the 1, 332 women that participated in the clinical trials contracted HIV.

Due to the sensitivity and repercussions of the issue, the Ministry of Health has remained tight-lipped on the outcome of the trials.

A vaginal microbicide is a product intended for use before sexual intercourse to reduce HIV infection and they are supposed to be used with condoms and complement other prevention strategies such as behaviour change, abstinence and other preventive methods.

It should be noted that vaginal microbicide should not be used alone or replace correct and consistent use of condoms in the fight against HIV and Aids, said Dr Swebby Macha – a gynaecologist at Zambia’s University Teaching Hospital (UTH) in Lusaka, the largest hospital in the country.

The participants in the clinical trial were either assigned the PRO2000 gel or placebo gel (with inactive ingredient) and were instructed to apply gel about one hour before sexual intercourse.

The gel contains molecules that are intended to cluster around the virus before it can penetrate the vaginal wall.

To be effective, the women were counselled on safe sexual behaviour and encouraged to use condoms, which were provided free of charge.

According to Dr Macha, this clinical trial found that the risk of HIV infection in women that were supplied with PRO2000 gel was not significantly different than women supplied with placebo gel.

“The largest international clinical trial to date into a preventive HIV gel has found no evidence that the vaginal microbicide, PRO2000, reduces the risk of HIV infection in women,” said Dr Macha, the former president of Zambia Medical Association (ZMA).

Dr Macha said to date no microbicide had been proved to be effective against HIV infection.

A local traditional ruler has demanded compensation for the infected women and prosecution of architects of the clinical trial.

Chief Mwanachingwala of the Tonga people in Mazabuka district where the clinical trials took place said the women that took part in the trials were “poor and uneducated” and did not know the consequences of the research, which has left some of them infected.

But Ministry of Health officials, speaking on anonymity basis, argued that MDP followed the laid down legal and clinical procedures, therefore, were not liable to prosecution over the outcome of clinical trials.

In an explanatory statement, Dr Chisembele said that during the clinical trial, a lot of emphasis was put on the fact that it was unknown whether PRO2000 gel would work to prevent HIV.

The infection of the 46 women has drawn outrage from many Zambians who are accusing MDP of using some African women as “guinea pig” because they are poor and ignorant.

Zambia is among African countries hardest hit by Hiv infections with prevalence rate of 14.3 per cent of its population estimated at about 13 million people.

Share and Enjoy:
  • Print
  • Digg
  • del.icio.us
  • Facebook
  • StumbleUpon
  • Twitter
  • Yahoo! Buzz
  • PDF
  • LinkedIn
  • Live
  • NewsVine
WHO Confirms D225G Vaccine Failure

Vaccine Development, Vaccine Snafus

WHO Confirms D225G Vaccine Failure

2 Comments 01 December 2009

Source: Recombinomics Commentary
November 28, 2009

One isolate from Ukraine with the mutation had changed so that swine flu vaccine probably would not protect against it well, Britain’s national medical laboratory reported Friday.

Flus mutate so fast, Dr. Fukuda cautioned, that announcing each change is “like reporting changes in the weather.”

The above quote from tomorrow’s NY Times piece by Donald McNeil, acknowledges the vaccine failure for viruses with D225G.  However, although WHO has publicly confirmed the failure, they don’t think an announcement is required.  Thus, they continue to offer altering opinions on the significance of D225G, which directs H1N1 to the lung and was present in four of four fatalities in Ukraine.

The associate of D225G with the Ukraine fatalities led to a survey of samples in Norway, where D225G was found in three patients (two who died and 1 who was in serious condition).  Similarly, France found D225G in two fatal infections, including one who was Tamiflu resistant.

However, even though this change is drawing additional attention daily, WHO has taken a position that the vaccine failure against H1N1 with this D225G is not worthy of an announcement.

This mindset is significant cause for concern and is hazardous to the world’s health.

Share and Enjoy:
  • Print
  • Digg
  • del.icio.us
  • Facebook
  • StumbleUpon
  • Twitter
  • Yahoo! Buzz
  • PDF
  • LinkedIn
  • Live
  • NewsVine

H1N1, News, Vaccine Snafus

2 NYC Students Get Swine Flu Vaccine Without Consent Form

No Comments 30 October 2009

myfoxny.com
Updated: Thursday, 29 Oct 2009, 11:57 PM EDT
Published : Thursday, 29 Oct 2009, 7:11 PM EDT

MYFOXNY.COM – Two elementary school students have been given the H1N1 swine influenza vaccine without proper parental consent, according to New York City officials.

In a joint statement from the Health and Education departments, officials said that 1,800 schoolchildren have been vaccinated this week, and that one student at a school on Brooklyn and another on Staten Island didn’t have permission from their parents.

The children did not suffer any bad affects, said Erin Brady of the Health Department, “but we are working to determine how this misstep occurred, and we will develop additional safeguards to prevent similar instances in the future.”

The two schools were P.S. 335 at 130 Rochester Avenue in Brooklyn and P.S. 65 (the Academy of Innovative Learning) at 98 Grant Street on Staten Island.

Nurses are required to confirm parental consent and review each child’s health screening information before administering the vaccine.

Earlier this week, Health Department officials said that fewer than half of school parents have returned signed consent forms, indicating either a lack of proper information or concern about the vaccine’s safety.

Weekend vaccine clinics for middle-school and high-school students will be held in each borough during November and December, officials said.

Share and Enjoy:
  • Print
  • Digg
  • del.icio.us
  • Facebook
  • StumbleUpon
  • Twitter
  • Yahoo! Buzz
  • PDF
  • LinkedIn
  • Live
  • NewsVine

By Reactions, News, Vaccine Snafus

FIFTH “SWINE FLU” VACCINE DEATH IN SWEDEN – VACCINATIONS STILL GO AHEAD AS PLANNED!

No Comments 28 October 2009

Fifth “swine flu” vaccine death in Sweden – vaccinations still go ahead as planned!

Media in Sweden is having a tough time maintaining the propaganda as more and more people question the reasons for the mass vaccination. Now, authorities say that if not “80% of the population takes the shot, we risk 100 deaths from the swine flu”. Most Swedes know that a normal flu season see several thousand dead from complications from the seasonal flu so the proportions of the propaganda coming from media and the government has caused a growing revolt against the massive attempts to scare people to take the poisonous injection.

We have earlier reported on the first death, the second death (also here), the third death and the fourth death in Sweden from the poisonous Pandemrix vaccin shot.

Today, Svenska Dagbladet reports that over 350 cases of side effects from the Pandemrix “swine flu” shot, has been recorded so far. It has also become clear that this shot contains the most deadly mix of substances of all the known vaccines manufactured against the so called “swine flu” H1N1 influenza. The official number of deaths from the “swine flu” vaccine is now five. And that is only those who have strong immediate reactons, the long term effects are usually never even investigated. If you would die from the shot two weeks after you took it, your death would not be considered to have anything to do with the vaccination. Severe health problems years after will of course be very hard to link to the poisonous injection. Even if these five official cases died within days, the official story is of course as expected: “none of these deaths has been confirmed to be linked to the vaccine”.

In Aftonbladet, Jan Liliemark from The Swedish Institute for Infectious Disease Control (SMI) says: “- Nothing points to a connection. There will be more deaths. We are looking for a pattern, if the cases have something in common. We have so far not found any clear connections between them yet.”  Officially 198 cases of confirmed “swine flu” exist in Sweden today among a population of over 9 million. How these cases have been tested and determined is not clear.

As always with statistics like this, historically we know that very few of all real side effects are actually reported. Optimistically, up to ten per cent would be reported. It is also highly likely that deaths are being kept secret by the authorities so that the massive and hugely expensive vaccination program will not come to a complete stop. Too many have put their job, reputation and title at stake for the truth to be reported and published.

So far, three people have been reported dead from complications from getting the H1N1 virus.  Five dead from the flu shot before the real vaccination campaign has even started should be an indication to question the vaccine and the strategy chosen but the authorities have so much prestige invested that it is unlikely it will ever happen – no matter how many will die from the poisonous injections.

The Swedish public are being kept in the dark about the most simple facts about the vaccinations. The questionable protection against the virus will only be for this present strain – any new mutations would immediately require a new vaccine for that strain. The new second wave of the new mutation is exactly what authorities warn about and use as an argument to take the poisonous injection.

Authorities are running out of arguments and completely idiotic arguments have been published the last week in Sweden. “There is less mercury in the shot than you get from eating mercury contaminated fish”, “You might get sick from the vaccine but you should take that risk to ´save” someone who could die from getting the H1N1 infection from you”, “It would be like killing someone to not take the shot out of solidarity” and “Mercury is not dangerous and also squalene is not dangerous, there is nothing called the Gulf War Syndrome and if there is, it has nothing to do with squalene because there was no squalene in the vaccines the US troops got”, “German politicians will not get a different flu shot than the rest of the German population”.

The number of flat out lies are so many, it is hard to keep track of them all.

The chief of The Swedish Institute for Infectious Disease Control (SMI), Annika Linde, says in the article: “- The Vaccine is principally natural to the body. The mercury was necessary but the amounts are very small. There are many who have been making statements without qualified knowledge. It is of course good that this type of matter is debated but some of the reporting is rather devastating for the possibility to vaccinate the whole population.” You are welcome Mrs Linde.

The official line in Sweden is bordering to madness and the biggest medical scandal in the history of the nation has just started.

Johan Niklasson

Share and Enjoy:
  • Print
  • Digg
  • del.icio.us
  • Facebook
  • StumbleUpon
  • Twitter
  • Yahoo! Buzz
  • PDF
  • LinkedIn
  • Live
  • NewsVine

H1N1, News, Vaccine Snafus

Novartis denies problems with swine flu vaccine

No Comments 27 October 2009

Novartis denies problems with swine flu vaccine
October 26th, 2009

Swiss pharmaceutical group Novartis on Monday denied that it faced hurdles in gaining regulatory approval in Switzerland for one of its swine flu vaccines because of possible bacterial contamination.

The vaccine, branded as Celtura, is produced by a technique using cell cultures from dog kidneys, allowing more rapid production than by the more classical method using chicken eggs, according to the company.

Citing anonymous sources close to the case, the Swiss daily Tages-Anzeiger reported on Saturday that the Swiss authority overseeing medicines and therapeutical products, Swissmedic, had found in test batches of Celtura.

A spokesman at Swissmedic told AFP that the agency could “neither confirm nor deny” the report.

Swissmedic is due to give its authorisation for the vaccine this week ahead of a mass vaccination campaign against influenza A(H1N1) in Switzerland.

A spokesman for Novartis, Eric Althoff, insisted on Monday that the Celtura vaccine was not contaminated.

“There is no contamination of Celtura, the process is much cleaner than by chicken eggs,” he told AFP.

Novartis is hoping for the green light to market the vaccine from Swiss health authorities in the coming days and from the European Union in the next few weeks.

The spokesman insisted that the production process was the same as that which has been used on a seasonal flu vaccine for several years.

About 8,000 people have taken part in clinical trials of A(H1N1) vaccines, he added.

Novartis already markets another swine in Europe under the brand name Focetria, which is based on chicken egg cultures.

Share and Enjoy:
  • Print
  • Digg
  • del.icio.us
  • Facebook
  • StumbleUpon
  • Twitter
  • Yahoo! Buzz
  • PDF
  • LinkedIn
  • Live
  • NewsVine

H1N1, Medical Cartel, Vaccine Snafus

Child vaccinated with H1N1 at school AGAINST PARENTS WISHES!

1 Comment 26 October 2009



Share and Enjoy:
  • Print
  • Digg
  • del.icio.us
  • Facebook
  • StumbleUpon
  • Twitter
  • Yahoo! Buzz
  • PDF
  • LinkedIn
  • Live
  • NewsVine

H1N1, News, Vaccine Snafus

Vaccine Organisation: Pregnant Women Administered Wrong Swine Flu Vaccine

2 Comments 23 October 2009

YLE.fi

The National Institute for Health and Welfare (THL) is providing pregnant women with the wrong swine flu vaccine, according to the non-profit vaccine awareness organisation Rokotusinfo. However, THL researcher Petri Ruutu insists the vaccine is safe.

The organisation claims that Finland has failed to order the vaccine recommended for pregnant women by the World Health Organization (WHO). The WHO recommends that pregnant women primarily be given a vaccine that does not contain an adjuvant, an additive that bolsters the body’s immune response to the vaccine.

Side effects of the adjuvant have not been studied in pregnant women or unborn children.

Rokotusinfo also claims that the THL has provided misinformation on the side effects of the vaccine. The organisation says the side effects of the swine flu vaccine are up to ten times greater than side effects for regular seasonal influenza.

In addition, Rokotusinfo says that the THL ordered the Pandemrix vaccine for the entire Finnish population without the opportunity for competitive bidding.

Meanwhile, THL researcher Petri Ruutu told YLE’s Morning TV talk show on Thursday that the vaccine is safe.

“The risks of the vaccine are less than the risks of an epidemic,” he says.

Read Story on YLE.

Share and Enjoy:
  • Print
  • Digg
  • del.icio.us
  • Facebook
  • StumbleUpon
  • Twitter
  • Yahoo! Buzz
  • PDF
  • LinkedIn
  • Live
  • NewsVine

Newsletter

Click to Join Our Newsletter! Carl Bruning Constitutional Larimer County Sheriff

Users Online

Featured Vaccine Book

Dr. Todd Elsner's Book

 

Today, according to the CDC’s recommended vaccination schedule, a child receives 36 shots containing a total of 126 vaccines from birth through six years of age. This is quadruple the number of vaccines a child received in the 1980’s. In 1983 a child received only 10 shots containing 30 vaccines.

Could this quadrupling of the schedule be responsible for the drastic increase in childhood disorders we are seeing today?

 

Get the information your pediatrician will never tell you!

Live Healthy

Award Winning Inspirational Documentary by Valya Boutenko
Best Selling Books and DVDs from the Raw Family

Ads

Silver Lungs

Optimize Your Health

Vibrant Living with Delicious Green Smoothies